Bridgefront Capital, LLC Mannkind Corp Transaction History
Bridgefront Capital, LLC
- $312 Million
- Q3 2025
Shares
2 transactions
Others Institutions Holding MNKD
# of Institutions
257Shares Held
165MCall Options Held
2.76MPut Options Held
689K-
Black Rock Inc. New York, NY22.6MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.6MShares$89.2 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY11.4MShares$57.8 Million1.01% of portfolio
-
State Street Corp Boston, MA10.7MShares$54.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA7.39MShares$37.4 Million0.0% of portfolio
About MANNKIND CORP
- Ticker MNKD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 257,338,000
- Market Cap $1.3B
- Description
- MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...